Application of 18F-FDG PET/CT in diagnosis of bone metastases of unknown primary tumor
-
摘要:
目的 探讨18氟-脱氧葡萄糖PET/CT在原发灶不明的骨转移瘤(BMUPT)患者中的应用价值,并总结BMUPT患者PET/CT图像特征。 方法 回顾性分析本院PET/CT中心检查的49例原发灶不明的骨转移瘤患者的影像资料,记录其原发灶部位、淋巴结转移、远处脏器转移、骨转移部位及骨转移性质,同时测定各骨转移灶最大标准化摄取值(SUVmax),对不同骨转移性质及部位的SUVmax做统计学分析。 结果 PET/CT检查共正确检出48例原发灶, 有1例未正确检出,新发现42例合并淋巴结转移,26例合并器官转移。49例患者中成骨性转移9例,溶骨性转移33例,混合性转移7例。各部位骨转移发生率依次为:脊柱91.8%、骨盆85.7%、胸部77.5%、四肢57.1%、颅骨24.4%。溶骨性转移SUVmax大于成骨性转移(t=3.55,P<0.05)。成骨性转移、溶骨性转移各部位之间SUVmax差异均无统计学意义(P>0.05)。 结论 PET/CT在BMUPT的原发灶寻找中具有很高的准确性,且能发现新的淋巴结及远处转移灶,可以BMUPT患者病情评估及综合治疗提供更全面的价值。 -
关键词:
- 18氟-脱氧葡萄糖 /
- 正电子发射型计算机断层显像/计算机体层成像 /
- 骨转移瘤 /
- 不明原发灶
Abstract:Objective To investigate the clinical value of 18F-fluorodeoxyglucose(18F-FDG) positron emission tomography/computed tomography(PET/CT) in diagnosis of bone metastases of unknown primary tumor(BMUPT), and summarize the features of PET/CT findings in patients with BMUPT. Methods The imaging data of 49 patients with BMUPT in our hospital were retrospectively analyzed. Primary tumor sites, lymph nodes metastases, organ metastases and bone metastases were recorded. The maximum standardized uptake value(SUVmax) of each bone metastasis were determined and the SUVmax of different bone metastases properties and metastases sites were statistically analyzed. Results Forty-eight cases of primary tumor were correctly detected by PET/CT, 1 case was not correctly detected. 42 cases were newly found with lymph nodes metastases and 26 cases were found with organ metastasis. Among the 49 patients, there were 9 cases of osteogenic metastases, 33 cases of osteolytic metastases and 7 cases of mixed metastases.Incidence of bone metastasis in each place was spine>pelvis>chest>limbs>skull. The SUVmax of osteolytic metastases was higher than that of osteogenic metastases(t=3.55, P<0.05). Differences of SUVmax between osteogenic and osteolytic metastasis at the sites of bone metastases was not significant(P>0.05). Conclusion PET/CT has a high accuracy in diagnosis for a primary tumor of BMUPT.It can find new lymph nodes and organ metastases, which provides more comprehensive value for the evaluation and treatment of BMUPT patients. -
表 1 骨转移原发病灶及转移类型
转移方式 总例数n(%) 原发灶(n) 成骨性转移 9(18.4) 前列腺癌(6) 肺癌(1) 胃癌(1) 乳腺癌(1) 溶骨性转移 33(67.3) 肺癌(16) 胃癌(5) 肝癌(3) 肾癌(2) 鼻咽癌(1) 宫颈癌(1) 甲状腺癌(1) 前列腺癌(1) 乳腺癌(1) 胰腺癌(1) 臀尾部平滑肌肉瘤(1) 假阳性(1) 混合性转移 7(14.3) 肺癌(4) 胃癌(2) 前列腺癌(1) 表 2 各部位骨转移瘤SUVmax比较
转移方式 脊柱(n=45) 骨盆(n=42) 胸部(n=38) 四肢(n=28) 颅骨(n=12) F P 溶骨性转移 10.54±3.36 9.91±3.98 8.55±3.86 8.74±3.41 9.80±2.68 1.563 0.189 成骨性转移 7.50±4.10 6.54±2.67 6.11±3.43 6.68±3.69 6.57±2.82 0.387 0.817 -
[1] 吴小红, 华 东, 陈晓萍. 原发灶不明的骨转移性癌24例分析[J]. 肿瘤防治杂志, 2004, 11(04): 446-7. doi: 10.3969/j.issn.1673-5269.2004.04.044 [2] 谢纪宝, 陈江涛, 宋兴华. 18F-FDG PET/CT与99mTc-MDP骨显像诊断肿瘤骨转移价值的Meta分析[J]. 中国循证医学杂志, 2011, 11(06): 655-60. doi: 10.3969/j.issn.1672-2531.2011.06.012 [3] 任媛, 王莉莉, 郑永明. 原发灶不明的骨转移癌核素骨显像结果分析[J]. 长治医学院学报, 2007, 21(06): 453-4. doi: 10.3969/j.issn.1006-0588.2007.06.024 [4] 曹来宾. 实用骨关节影像诊断学[M]. 济南: 山东科学技术出版社, 1998: 411-3. [5] 李鹏飞. 恶性肿瘤1000例骨扫描结果分析[J]. 中外医学研究, 2011, 9(19): 22-3. doi: 10.3969/j.issn.1674-6805.2011.19.013 [6] Piccioli A. Breast cancer bone metastases: an orthopedic emergency[J]. Orthop Traumatol, 2014, 15(2): 143-4. doi: 10.1007/s10195-013-0283-6.pdf [7] Xu DL, Zhang XT, Wang GH, et al. Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases[J]. Cancer, 2005, 24(11): 1404-7. https://www.researchgate.net/publication/7226039_Clinical_features_of_pathologically_confirmed_metastatic_bone_tumors--a_report_of_390_cases [8] Katagiri H, Takahashi M, Inagaki J, et al. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study[J]. Cancer, 1999, 86(3): 533-7. doi: 10.1002/(ISSN)1097-0142 [9] Papagelopoulos PJ, Savvidou OD, Galanis EC, et al. Advances and challenges in diagnosis and management of skeletal metastases[J]. Orthopedics, 2006, 29(7): 609-20. https://jhu.pure.elsevier.com/en/publications/advances-and-challenges-in-diagnosis-and-management-of-skeletal-m-4 [10] Chorost MI, Lee MC, Yeoh CB, et al. Unknown primary[J]. Surg Oncol, 2004, 87(10): 191-203. [11] Sève P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positronemission tomography in disseminated carcinoma of unknown primary site[J]. Cancer, 2007, 109(2): 292-9. doi: 10.1002/(ISSN)1097-0142 [12] Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy[J]. Eur Radiol, 2011, 21(12): 2604-17. doi: 10.1007/s00330-011-2221-4 [13] Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma[J]. Clin Nucl Med, 2013, 38(8): 616-21. doi: 10.1097/RLU.0b013e31828da5cc [14] Chang CY, Gill CM, Joseph SF, et al. Comparison of the diagnostic accuracy of 99mTc-MDP bone scintigraphy and 18F-FDG PET/CT for the detection of skeletal metastases[J]. Acta radiol, 2016, 57(1): 58-65. doi: 10.1177/0284185114564438 [15] Hurley C, Mccarville B, Shulkin BL, et al. Comparison of F-18-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma[J]. Pediatr Blood Cancer, 2015, 33(15, S): 1381-6. https://www.researchgate.net/publication/292721628_Comparison_of_18_F-FDG-PET-CT_and_Bone_Scintigraphy_for_Evaluation_of_Osseous_Metastases_in_Newly_Diagnosed_and_Recurrent_Osteosarcoma [16] 李毅红, 刘春利, 卫建国, 等. 18F-FDG PET/CT对原发灶不明的骨转移瘤的诊断价值[J]. 中国医学影像学杂志, 2012, 20(11): 858-61. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zgyxyxjs200904048 [17] 徐 亭, 张艳桥. 胃癌骨转移的临床研究进展[J]. 中国肿瘤, 2016, 25(08): 628-33. http://edu.wanfangdata.com.cn/Periodical/Detail/djjk-x201606424 [18] Lucia D, Antonietta SM, Caterina M, et al. Bone metastases in gastriccancer follow a RANKL-independent mechanism[J]. Oncol Rep, 2013, 29(4): 1453-8. doi: 10.3892/or.2013.2280 [19] Ricci E, Mattei E, Dumontet C, et al. Increased expression of putative cancerstem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression[J]. Prostate, 2013, 73(16): 1738-46. doi: 10.1002/pros.v73.16 [20] Wang N, Docherty FE, Brown HK, et al. Prostate cancer cells preferentiallyhome to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models[J]. Bone Miner. Res, 2014, 29(12): 2688-96. doi: 10.1002/jbmr.2300 [21] Faltermeier CM, Drake JM, Clark PM, et al. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis[J]. Proc Natl Acad Sci USA, 2016, 113(2): E172-81. doi: 10.1073/pnas.1521674112 [22] 韩 萍, 张幸平. 肺癌骨转移机制的研究进展[J]. 重庆医学, 2009, 38(08): 992-4. doi: 10.3969/j.issn.1671-8348.2009.08.052 [23] Luo QQ, Xu ZY, Wang LF, et al. Progress in the research on the mechanism of bone metastasis in lung cancer[J]. Mol Clin Oncol, 2016, 5(2): 227-35. doi: 10.3892/mco.2016.917 [24] Gj C, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18-FDG PET: differing metabolic activityin osterblastic and osteolytic lesions[J]. Clin Oncol, 1998, 16(10): 3375-9. doi: 10.1200/JCO.1998.16.10.3375 [25] 宋 乐, 袁慧书, 张卫方. 前列腺癌骨转移18F-FDG PET/CT临床应用分析[J]. 临床放射学杂志, 2016, 35(05): 768-71. http://journal.9med.net/html/qikan/yykxzh/jlyx/201093117/lcyj/20100830090846518_542995.html [26] Samarin A, Huellner M, Queiroz MA, et al. F-18-FDG-PET/Mr increases diagnostic confidence in detection of bone metastases compared with F-18-FDG-PET/CT[J]. Nucl Med Commun, 2015, 36(12): 1165-73. doi: 10.1097/MNM.0000000000000387